Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor

Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor

Abstract Background The cholecystokinin receptor subtype 2 (CCK-2R) is an important target for diagnostic imaging and targeted radionuclide therapy (TRNT) due to its overexpression in certain cancers (e.g., medullary thyroid carcinoma (MTC)), thus matching with a theranostic principle. Several pepti...

Full description

Bibliographic Details
Main Authors:	Piotr F. J. Lipiński, Piotr Garnuszek, Michał Maurin, Raphael Stoll, Nils Metzler-Nolte, Artur Wodyński, Jan Cz. Dobrowolski, Marta K. Dudek, Monika Orzełowska, Renata Mikołajczak
Format:	Article
Language:	English
Published:	SpringerOpen 2018-04-01
Series:	EJNMMI Research
Subjects:	Minigastrin analogue Medullary thyroid carcinoma Cholecystokinin receptor subtype 2 Molecular docking
Online Access:	http://link.springer.com/article/10.1186/s13550-018-0387-3

Similar Items

Investigation of the structure-activity relationship at the N-terminal part of minigastrin analogs
by: Nadine Holzleitner, et al.
Published: (2023-07-01)

Significant reduction of activity retention in the kidneys via optimized linker sequences in radiohybrid-based minigastrin analogs
by: Nadine Holzleitner, et al.
Published: (2024-03-01)

Introduction of a SiFA Moiety into the D-Glutamate Chain of DOTA-PP-F11N Results in Radiohybrid-Based CCK-2R-Targeted Compounds with Improved Pharmacokinetics In Vivo
by: Nadine Holzleitner, et al.
Published: (2022-11-01)

Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs
by: Taraneh Sadat Zavvar, et al.
Published: (2023-02-01)

Radiopharmaceutical Formulation and Preclinical Testing of <sup>68</sup>Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial
by: Anton A. Hörmann, et al.
Published: (2021-06-01)

Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin <sup>177</sup>Lu-PP-F11N
by: Nathalie M. Grob, et al.
Published: (2021-05-01)

Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177
by: Anton Amadeus Hörmann, et al.
Published: (2020-10-01)

Automated Synthesis of <sup>68</sup>Ga-Labeled DOTA-MGS8 and Preclinical Characterization of Cholecystokinin-2 Receptor Targeting
by: Anton Amadeus Hörmann, et al.
Published: (2022-03-01)

Evaluation of Actinium-225 Labeled Minigastrin Analogue [<sup>225</sup>Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy
by: Yun Qin, et al.
Published: (2020-11-01)

Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m
by: Maximilian Klingler, et al.
Published: (2019-01-01)

Development of the First <sup>18</sup>F-Labeled Radiohybrid-Based Minigastrin Derivative with High Target Affinity and Tumor Accumulation by Substitution of the Chelating Moiety
by: Thomas Günther, et al.
Published: (2023-03-01)

Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [<sup>177</sup>Lu]Lu-PP-F11N
by: Michal Grzmil, et al.
Published: (2021-12-01)

Discovery of a Positive Allosteric Modulator of Cholecystokinin Action at CCK1R in Normal and Elevated Cholesterol
by: Kaleeckal G. Harikumar, et al.
Published: (2021-12-01)

Cholecystokinin (CCK) and its receptors (CCK1R and CCK2R) in chickens: functional analysis and tissue expression
by: Yiping Wan, et al.
Published: (2023-01-01)

Expression of CCK Receptors in Carcinoma Gallbladder and Cholelithiasis: A Pilot Study
by: Mohammad Shazib Faridi, et al.
Published: (2015-07-01)

Neural circuit mechanisms of the cholecystokinin (CCK) neuropeptide system in addiction
by: Yihe Ma, et al.
Published: (2022-09-01)

CCK2 receptors in chronic pain
by: Justin E. LaVigne, et al.
Published: (2022-01-01)

Comparative density of CCK- and PV-GABA cells within the cortex and hippocampus
by: Paul David Whissell, et al.
Published: (2015-09-01)

CCK‐1 and CCK‐2 receptor agonism do not stimulate GLP‐1 and neurotensin secretion in the isolated perfused rat small intestine or GLP‐1 and PYY secretion in the rat colon
by: Ida M. Modvig, et al.
Published: (2020-01-01)

Neuronal Dystroglycan regulates postnatal development of CCK/cannabinoid receptor-1 interneurons
by: Daniel S. Miller, et al.
Published: (2021-08-01)

Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)
by: Michal Grzmil, et al.
Published: (2022-08-01)

Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals
by: Elisabeth von Guggenberg, et al.
Published: (2021-11-01)

Preliminary Study of a 1,5-Benzodiazepine-Derivative Labelled with Indium-111 for CCK-2 Receptor Targeting
by: Marco Verona, et al.
Published: (2021-02-01)

Radiooznačeni peptidi v nuklearni medicini
by: Marko Krošelj, et al.
Published: (2018-10-01)

Regulation of CCK-induced ERK1/2 activation by PKC epsilon in rat pancreatic acinar cells
by: Chenwei Li, et al.
Published: (2017-11-01)

Excess dietary Lys reduces feed intake, stimulates jejunal CCK secretion and alters essential and non-essential blood AA profile in pigs
by: Maximiliano Müller, et al.
Published: (2024-02-01)

CCK1-Receptor Stimulation Protects Against Gut Mediator-Induced Lung Damage During Endotoxemia
by: Friederike Eisner, et al.
Published: (2013-12-01)

Radiolabeled Peptides for Cancer Imaging and Therapy: From Bench-to-Bedside
by: Rosalba Mansi, et al.
Published: (2021-06-01)

The effects of CCK-8S on spatial memory and long-term potentiation at CA1 during induction of stress in rats
by: Malihe Sadeghi, et al.
Published: (2017-12-01)

Preclinical Evaluation of Ga-DOTA-Minigastrin for the Detection of Cholecystokinin-2/Gastrin Receptor-Positive Tumors
by: Maarten Brom, et al.
Published: (2011-03-01)

Effect of <i>N</i>-Terminal Peptide Modifications on In Vitro and In Vivo Properties of <sup>177</sup>Lu-Labeled Peptide Analogs Targeting CCK2R
by: Anton Amadeus Hörmann, et al.
Published: (2023-02-01)

Stearic acid induces CCK and GLP-1 upregulation via GPR120/PLC-β, leading to reduced appetite in Hu sheep fed with rice straw
by: Xi Chen, et al.
Published: (2022-09-01)

Targeted Radiotherapeutics from 'Bench-to-Bedside'
by: Cristina Müller, et al.
Published: (2020-12-01)

Supplementation with a fish protein hydrolysate (Micromesistius poutassou): effects on body weight, body composition, and CCK/GLP-1 secretion
by: Vincenzo Nobile, et al.
Published: (2016-01-01)

Clinical effects of central antagonist of cholecystokinin-1 receptors GB-115 in patients with Generalized Anxiety Disorder
by: O. Dorofeeva, et al.
Published: (2022-06-01)

Structure-activity relationship data and ligand-receptor interactions identify novel agonists consistent with sulfakinin tissue-specific signaling in Drosophila melanogaster heart
by: Ruthann Nichols, et al.
Published: (2022-05-01)

Mechanism of Action and Structure–Activity Relationships of Tetracyclic Small Molecules Acting as Universal Positive Allosteric Modulators of the Cholecystokinin Receptor
by: Daniela G. Dengler, et al.
Published: (2023-01-01)

The DOTA macrocyclic cavity in metallic radiopharmaceuticals: Mythology or reality?
by: Adriano Duatti
Published: (2023-08-01)

Satietogenic Protein from Tamarind Seeds Decreases Food Intake, Leptin Plasma and CCK-1r Gene Expression in Obese Wistar Rats
by: Izael S. Costa, et al.
Published: (2018-12-01)

Distribution of cionin, a cholecystokinin/gastrin family peptide, and its receptor in the central nervous system of Ciona intestinalis type A
by: Shiho Taniguchi, et al.
Published: (2024-03-01)